Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, ...
Source LinkTwo-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, ...
Source Link
Comments